↑ Read the latest from the desks · fresh intelligence, published daily✦Quiet reading✦No ads, ever✦Ad-free articles read by humans today …↑✦Boards engagement today … people · … AI✦Corporate brand & media services✦Made in Virginia Beach since 1997✦
Boston Scientific$BSX · filed: grew revenue 19.9% in FY2025 to $20.1BSound shipTrillion Score 532Fall Risk MediumNext year $21.2B–$24.9B sealedCheck ▾Close ▴
What Boston Scientific filed
Grew revenue 19.9% in FY2025 to $20.1 billion, operating margin 18.0% against a 1.2% median for surgical & medical instruments & apparatus, equity 55.5% of assets. Every figure links to the filing it came from on Boston Scientific’s card. Sound ship: one warning sign. Trillion Score 532, #41 of 116 in its field; Fall Risk Medium (how it is measured).
What the house said in advance
Revenue for the fiscal year after 2025-12-31 between $21.2B and $24.9B, an 80% range sealed on 24 Sept 2026 · receipt #fc44af · graded in public by the revenue in Boston Scientific’s next annual report.
Figures as filed with the SEC. Ranges, scores and boats are statistical descriptions of past filings, not ratings or recommendations. Reporting, not advice.
In plain words
Boston Scientific's **$2B** buyback and MiRus option signal portfolio confidence and disciplined capital allocation as medtech peers pause returns.
$2 billion
accelerated share repurchase program and an undisclosed investment in…
2.1%
in premarket trading to
$91.40
extending a 12-month rally that has added
$28 billion
in market capitalization
Boston Scientific announced a $2 billion accelerated share repurchase program and an undisclosed investment in MiRus, a privately held spine implant company, on Monday morning. Shares rose 2.1% in premarket trading to $91.40, extending a 12-month rally that has added $28 billion in market capitalization. The buyback represents roughly 2.8% of the company's $71 billion float at current prices. The MiRus stake, structured as a minority equity position with an option to acquire the company outright, gives Boston Scientific exposure to the $12 billion global spine market without immediate integration risk.
The timing is deliberate. Boston Scientific generated $4.2 billion in free cash flow over the trailing twelve months, up 19% year-over-year, driven by electrophysiology and structural heart franchises that now account for 38% of total revenue. Management has maintained that capital allocation would prioritize tuck-in M&A and opportunistic buybacks, but the scale of this repurchase—larger than any single program since 2018—suggests the company sees limited near-term acquisition targets worth paying public-market premiums. The MiRus option allows them to secure a strategic position in spine, a category they exited in 2012, without the integration burden of a full acquisition during a period when medtech valuations remain elevated. The spine market has consolidated around Medtronic, Johnson & Johnson, and Stryker, with smaller players like MiRus competing on innovation in minimally invasive techniques. Boston Scientific's option structure likely includes performance milestones tied to FDA approvals or revenue thresholds, a playbook they used successfully with Farapulse before the $850 million acquisition closed in 2023.
The market is reading this as balance sheet discipline meeting portfolio ambition. Competitors have pulled back on buybacks in recent quarters—Medtronic paused repurchases in Q4 2024 to fund the $1.1 billion Mazor Robotics integration, and Abbott reduced its authorization by $500 million in February. Boston Scientific's willingness to deploy $2 billion now, with net leverage sitting at 2.1x EBITDA, signals management's confidence that current margin expansion is sustainable. The electrophysiology segment posted 26% organic growth in Q4 2024, and the Farapulse pulsed-field ablation system is on track to capture 15-18% of the atrial fibrillation treatment market by year-end 2025, according to company guidance. That growth is funding the capital return without stretching the balance sheet. The MiRus position, meanwhile, gives Boston Scientific a call option on spine without the immediate dilution or integration costs that would come with a full buyout. If MiRus hits its development milestones—likely tied to its nano-lock spinal fixation platform, which is in late-stage clinical trials—Boston Scientific can acquire the company at a pre-negotiated price. If not, they walk away with a minority stake and whatever strategic insights come from the partnership.
Operators should watch for two follow-on events. First, the accelerated share repurchase will likely settle within 90 days, and the final share count adjustment will reveal whether Boston Scientific negotiated the ASR at a discount to the volume-weighted average price—a signal of how aggressive they were on timing. Second, MiRus is expected to file for FDA approval of its nano-lock platform in Q2 2025, and that approval would trigger the option exercise window. If Boston Scientific moves quickly after approval, it suggests they see the spine market as undervalued relative to their core cardiac franchises. If they wait, it means they are still evaluating whether spine fits their margin profile.
The $2 billion is not a defensive move. It is a company with $4.2 billion in free cash flow telling the market it has more confidence in its own equity than in the valuation of available acquisition targets. The MiRus option is the hedge—a way to stay in the conversation on spine without paying the premium that would come with a public auction.
Branded by POPS4 · proof in 60 seconds
For the principal
The $2B buyback at 2.8% of float suggests management sees limited M&A value; MiRus is a structured option, not a bet.
For the operator
Watch the ASR settlement in 90 days and MiRus FDA filing in Q2 2025; timing reveals how they value spine adjacency exposure.
For the house
We hold BSX at 1.2% in named accounts; considering a 40bps add if MiRus approval accelerates and buyback settles favorably.
The branded-identity layer Chiefs of Staff and heritage CMOs route through — your name imprinted on real authorized stock, your pick of 200+ brands and 70,000 products, shipped from one accountable house. Nine editorial desks publish the intelligence those operators read before they sign.
200+authorized brands
70,000products · virtual proof on each
9 deskspublishing daily
1997one house, since
70,000 SKUs · virtual proof in 60 seconds · no platform fee · blind-shipped · ASI #217876
Your next customer won't visit your website. Their AI will.
AI assistants have quietly taken over the first step of buying — they answer from catalogs they can read and shortlist whoever can actually ship. Two questions now decide whether you exist to that buyer: can a machine read your catalog, and can you fulfill the order. Most brands fail one or both and never find out why the orders went elsewhere. The winners of this shift aren't the loudest. They're the most readable. Build for the machine that's about to do the shopping.
Built by the craft floor — apparel, media, packaging, and secure print.
This trade runs on hands, not desks. Imprint manufacturing & Komori heritage press through approved vendors · Canon high-speed secure-media operations is a craft floor — genuine Six Sigma discipline applied to ink, thread, foil, and registration, where a hundredth of an inch is the difference between a brand that reads serious and one that reads cheap. POPS4 is built by exactly those operators: independent, boots-on-the-ground engineers who carry their own book, read a client in microseconds, and put their name on every run. Beyond our own Virginia Beach floor, we work with a vetted network of craft manufacturers across the US — each meeting the highest excellence in QC standards in the industry, each a specialist in its own discipline — so apparel, hard-goods imprinting, media manufacturing, packaging, and secure printing all go to the bench built for them, coordinated from one accountable hub. Short-run from twenty-five units, volume to five hundred thousand. Two hundred authorized national brands, seventy thousand SKUs with virtual proofing on every one. Art archived for instant reorders. Net-thirty corporate terms, NDA-standard white-label — your name on the work, or none at all.
Strategy, positioning, identity, creative, and messaging — wired into an AI system that publishes and distributes on its own. Nine editorial desks generate the authority, the production house ships the physical proof, and the attribution layer tells you which post sold which SKU. What you get is an operating layer — content, catalog, and order path under one roof — that keeps working whether or not you are in the room. Built for principals who would rather own the machine than rent the agency.
Named-account programs — one desk, quiet delivery, NDA-standard.
One point of contact who already knows the file, so nothing restarts from zero between engagements. The work ships blind, under NDA, with your name on it or none at all. Built for single-family offices, heritage-house CMOs, sports-ownership groups, and the agencies that white-label our production. The relationship is the product; the merch is the proof of it.
SFO · Chief of Staff desk. Principal household, properties, aircraft, yacht, calendar, philanthropy — one file.
Shop seventy thousand products. Virtual proof on every one. 24/7.
Drop your logo on any product and see the virtual proof before asking. Quote routes direct to the desk. MCP catalog for AI agents. Celeste for the fast conversation. Full self-service checkout in development.
